fda compounding semaglutide enforcement news november 2025 Congress Introduces SAFE Drugs Act of 2025, Expanding Oversight of Compounded GLP-1 Drugs and Telehealth Providers Compounded Semaglutide: Safety & Regulation

For small peptides like BPC-157, subcutaneous bioavailability is generally expected to be high this is the route used in nearly all of the systemic animal studies, and it is the benchmark against which oral is measured

Research & Evidence Published, peer-reviewed studies on DSIP

More serious but less common safety considerations observed across this drug class include a potential risk of pancreatitis, gallbladder-related conditions (such as gallstones/cholelithiasis), and based on animal studies a theoretical concern regarding thyroid C-cell tumours, though this has not been confirmed in human trials

How do you separate GLP-1 effects from normal training gains

Under the Inflation Reduction Act of 2022, the federal government can negotiate drug prices directly with a manufacturer for Medicare